AR047756A1 - Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos - Google Patents

Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos

Info

Publication number
AR047756A1
AR047756A1 ARP040102555A ARP040102555A AR047756A1 AR 047756 A1 AR047756 A1 AR 047756A1 AR P040102555 A ARP040102555 A AR P040102555A AR P040102555 A ARP040102555 A AR P040102555A AR 047756 A1 AR047756 A1 AR 047756A1
Authority
AR
Argentina
Prior art keywords
fvw
fviii
complex
liquid composition
stable liquid
Prior art date
Application number
ARP040102555A
Other languages
English (en)
Inventor
Gamon Salvador Grancha
Nieto Juan Ignacio Jorquera
Debart Pere Ristol
Riera Marta Massot
Original Assignee
Probitas Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probitas Pharma Sa filed Critical Probitas Pharma Sa
Publication of AR047756A1 publication Critical patent/AR047756A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

La composicion comprende un concentrado de factor VIII (FVIII) de factor von Willie Brand (FvW) o del complejo FVIII/FvW humanos con un quelante de metales, un ligando específico y preferentemente un inhibidor de proteasa.
ARP040102555A 2003-10-03 2004-07-20 Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos AR047756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302298A ES2229931B1 (es) 2003-10-03 2003-10-03 Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.

Publications (1)

Publication Number Publication Date
AR047756A1 true AR047756A1 (es) 2006-02-22

Family

ID=34307115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102555A AR047756A1 (es) 2003-10-03 2004-07-20 Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos

Country Status (13)

Country Link
US (1) US20050074866A1 (es)
EP (1) EP1522312B1 (es)
JP (1) JP4388875B2 (es)
AR (1) AR047756A1 (es)
AT (1) ATE357245T1 (es)
CA (1) CA2481593C (es)
DE (1) DE602004005392T2 (es)
ES (2) ES2229931B1 (es)
HK (1) HK1075406A1 (es)
MX (1) MXPA04009246A (es)
PL (1) PL1522312T3 (es)
PT (1) PT1522312E (es)
UY (1) UY28531A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN101952016A (zh) 2007-12-28 2011-01-19 巴克斯特国际公司 重组vwf配方
TWI670072B (zh) 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
DK3066119T3 (en) * 2013-11-08 2018-11-12 Csl Ltd NEW PROCEDURE FOR CONCENTRATION OF THE VON WILLEBRAND FACTOR OR COMPLEXES OF IT
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP4322918A1 (en) 2021-04-13 2024-02-21 Grifols Worldwide Operations Limited Liquid composition comprising factor viii or factor viii/von willebrand factor complex
AU2022326188A1 (en) * 2021-08-11 2024-02-22 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359463A (en) * 1980-11-26 1982-11-16 Rock Gail A Stabilization of Factor VIII activity in whole blood or blood plasma
JPS59116228A (ja) * 1982-12-24 1984-07-05 Green Cross Corp:The 血液凝固第８因子脂肪小体製剤の製法
AT379510B (de) * 1983-05-20 1986-01-27 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
CA2378751C (en) * 1999-07-13 2012-11-06 Biovitrum Ab Stable factor viii compositions

Also Published As

Publication number Publication date
HK1075406A1 (en) 2005-12-16
UY28531A1 (es) 2005-03-31
MXPA04009246A (es) 2005-04-06
ES2280924T3 (es) 2007-09-16
DE602004005392D1 (de) 2007-05-03
ES2229931A1 (es) 2005-04-16
EP1522312A1 (en) 2005-04-13
PL1522312T3 (pl) 2007-08-31
CA2481593A1 (en) 2005-04-03
JP2005112855A (ja) 2005-04-28
ATE357245T1 (de) 2007-04-15
PT1522312E (pt) 2007-06-19
CA2481593C (en) 2009-10-20
JP4388875B2 (ja) 2009-12-24
US20050074866A1 (en) 2005-04-07
EP1522312B1 (en) 2007-03-21
DE602004005392T2 (de) 2007-12-06
ES2229931B1 (es) 2006-01-16

Similar Documents

Publication Publication Date Title
AR047756A1 (es) Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
YU68002A (sh) Modifikovani faktor viii
SE9802729D0 (sv) Novel Compounds
ATE476495T1 (de) Bazillus thuringiensis und dessen insektizide proteine
NO20034128L (no) Stabiliserte bestanddeler som gir aroma og n¶ringsmidler som inneholder detsamme
ATE356130T1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
AU8738401A (en) Novel kallikrein gene
NO20044898L (no) Nye etonogestrel estere
DE69906944D1 (de) 20-hete antagonisten und agonisten
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
MXPA03010158A (es) Sulfonamidas.
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
AP1696A (en) Agrochemical formulations comprising ALS inhibitors.
AU144678S (en) Bottle
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
CA99017S (en) Bottle with pump
DE60324816D1 (de) Impfstoffe gegen allergien
HUP0300775A2 (hu) Műanyag palack elsősorban italok tárolásához
DE60128367D1 (de) Verfahren und zwischenprodukte zur herstellung von retroviralen proteaseinhibitoren

Legal Events

Date Code Title Description
FC Refusal